SAN DIEGO, Nov. 29, 2010 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will participate in an informal "fireside chat" with research analyst Edward Tenthoff at Piper Jaffray's 22nd Annual Health Care Conference. The discussion will take place at 10:30 a.m. ET on Tuesday, November 30 at the New York Palace Hotel in New York City.
About Trius Therapeutics
Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. The company's lead product candidate, torezolid phosphate, is an IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of acute bacterial skin and skin structure infections (ABSSSI), the first such trial to be initiated under a Special Protocol Assessment (SPA). In addition to the company's torezolid phosphate clinical program, it is currently conducting two preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused by gram-negative bacteria. For more information, visit .
CONTACT: Canale Communications, Inc. Public Relations Contact: Jason Spark 619-849-6005 jason@canalecomm.com Westwicke Partners, LLC Investor Relations Contact: Stefan Loren 443-213-0507 sloren@westwicke.com